| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | 9.437 | 11.553 | 9.170 | 10.073 | 13.265 | 13.400 |
| Total Income - EUR | - | - | - | - | 9.437 | 11.553 | 9.170 | 10.073 | 13.265 | 14.826 |
| Total Expenses - EUR | - | - | - | - | 10.005 | 9.874 | 4.999 | 7.455 | 11.185 | 11.847 |
| Gross Profit/Loss - EUR | - | - | - | - | -567 | 1.679 | 4.171 | 2.618 | 2.079 | 2.979 |
| Net Profit/Loss - EUR | - | - | - | - | -574 | 1.638 | 4.106 | 2.437 | 1.959 | 2.845 |
| Employees | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 0 |
Check the financial reports for the company - Biocriomed S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | 11.693 | 9.790 | 7.928 | 6.353 | 4.993 | 3.539 |
| Current Assets | - | - | - | - | 3.162 | 1.282 | 4.998 | 7.574 | 9.790 | 12.942 |
| Inventories | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | - | 0 | 0 | 0 | 0 | 8.087 | 8.041 |
| Cash | - | - | - | - | 3.162 | 1.282 | 4.998 | 7.574 | 1.704 | 4.901 |
| Shareholders Funds | - | - | - | - | -532 | 1.116 | 5.196 | 7.650 | 9.586 | 12.377 |
| Social Capital | - | - | - | - | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | 1.030 | 621 | 247 | 558 | 693 | 1.051 |
| Income in Advance | - | - | - | - | 14.358 | 9.335 | 7.483 | 5.719 | 4.504 | 3.053 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8690 - 8690" | |||||||||
| CAEN Financial Year |
8690
|
|||||||||
Comments - Biocriomed S.r.l.